Please login to the form below

Not currently logged in
Email:
Password:

Galbraith settles with Cohn & Wolfe

Rebecca Galbraith has settled court proceedings issued by global public relations agency Cohn & Wolfe, where she used to be board director

Rebecca Galbraith has settled court proceedings issued by the global public relations agency Cohn & Wolfe (C&W), where she was previously a board director.

Galbraith had been dismissed on grounds of gross misconduct a month after she handed in her notice at the agency.

In the proceedings at the high court, C&W alleged that Galbraith "acted in breach of contract and fiduciary duty by misappropriating proprietary information belonging to Cohn & Wolfe and preparing to actively compete with the agency while sitting as a board director."

As reported in PR Week, Galbraith said: "Firstly I wish to apologise unreservedly to Cohn & Wolfe and WPP for my actions, but secondly I wish to the apologise to the Cohn & Wolfe team in London."

She continued: "I accept my conduct was in breach of my legal obligations. I acknowledge I removed proprietary information belonging to Cohn & Wolfe but confirm that I did not open or disseminate that information to any third parties."

Galbraith has paid an undisclosed settlement. Her apology follows those of fellow former board directors, Fiona McMillan, who settled out of court on April 20 and, Jeremy Clark, who settled out of court on April 16.

4th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics